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Abstract 
Background: The choice to recommend antithrombotic therapy to patients with atrial 
fibrillation should rely on cardio-embolic and bleeding risk stratification. Sharing some 
risk factors, schemes to predict thrombotic and bleeding risk are expected not to be 
independent, yet the degree of their association has never been clearly quantified. 
Methods: We described the cardio-embolic (CHADS2/CHA2DS2-VASc) and bleeding 
risk (HAS-BLED) co-distribution among patients of Euro Heart Survey on atrial 
fibrillation. We measured the within patient correlation (Spearman) and concordance 
between the two types of score and score-based risk categorization (low, intermediate, 
high). The score-based predicted risk co-classification was then related to the observed 1-
year stroke and bleeding occurrence.  
Results: In 3,920 patients, we found a between scores correlation of 0.416 (p<0.001) 
between HAS-BLED and CHADS2, and 0.512 (p<0.001) between HAS-BLED and 
CHA2DS2-VASc. In 89% (CHADS2/HAS-BLED) and 97% (CHA2DS2-VASc/HAS-
BLED) of patients the bleeding risk category was equal or lower than their cardio-
embolic risk category (p<0.001 for symmetry test). A complete concordance between risk 
categories was found in 39.6% (CHADS2/HAS-BLED) and 21.7% (CHA2DS2-
VASc/HAS-BLED); 4.4% (CHADS2/HAS-BLED) and 7.7% (CHA2DS2-VASc/HAS-
BLED) of patients had high cardio-embolic risk/low bleeding risk or vice-versa. A 
tendency of an increasing frequency of stroke was observed for increasing bleeding risk 
within cardio-embolic risk categories, and vice-versa. 
Conclusion: In a real-world atrial fibrillation population, we confirmed that the cardio-
embolic and bleeding risk classifications are correlated, but not exchangeable. It is then 
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worth verifying the advantages of a strategy adopting a combined risk assessment over a 
strategy relying only on the cardio-embolic risk evaluation. 
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Introduction 
Patients with atrial fibrillation may differently benefit from long term 
anticoagulation according to the balance of their baseline risk for stroke and for bleeding. 
With the availability of newer anticoagulants, the choice might be not only to treat or not, 
but which treatment choice fits better the risk profile. 
Strategies for treatment individualization, based on a trade-off between the 
treatment-related individual benefit and harm, are facilitated by the availability of clinical 
tools to predict the patient risk for the target and the adverse event. The CHADS2 
(Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or 
transient ischemic attack)1 and the CHA2DS2-VASc (Congestive heart failure, 
Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack, 
Vascular disease, Age 65-75, Sex category i.e. females)2 scores are two clinical risk 
factor-based schemes to predict the risk of stroke in patients with atrial fibrillation, 
included in the guidelines for the antithrombotic therapy of major Scientific Societies.3-5  
Noticeably, the CHA2DS2-VASc was developed to better identify patients “truly at low 
risk” of stroke,6 and this score is recommended in the ESC3 and Asia Pacific Heart 
Rhythm Society (APHRS) guidelines.7 
Several scores for the assessment of bleeding risk in patients with atrial 
fibrillation are also available in the literature.8-11 The HAS-BLED (Hypertension, 
Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile 
international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly) score 
was shown to have a good predictive ability both in patients on and off oral 
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anticoagulants12, and its use is recommended in the most recent European and Canadian 
guidelines.3,4 
Schemes for thrombotic and bleeding risk assessment have some risk factors in 
common, and there is evidence that these scores are in fact associated with both the risk 
of stroke and the risk of bleeding.13-16 Whether and to what extent the joint use of a score 
for the cardio-embolic risk and a score for the bleeding risk offers an advantage in 
making clinical decisions in clinical practice, in terms of risk stratification and treatment 
individualization, over a strategy relying only on the cardio-embolic risk assessment is 
not definitely clear. Surely it is affected by the co-distribution of the two scores, which 
needs to be assessed in a ‘real-word’ population.  
With these objectives, we first described how a population of atrial fibrillation 
patients referred to the hospital was classified by a combined use of a score for cardio-
embolic risk and a score for bleeding risk. Second, we measured the within patient 
correlation and concordance between the two types of score and score-based risk 
categorization. Third, we related outcomes of stroke and bleeding to the score-based risk 
co-classification.  
 
Methods 
Study population.  
We analyzed the Euro Heart Survey (EHS) on atrial fibrillation database, which included 
data on 5,333 inpatients or outpatients, ≥ 18 years old, referred to 182 university, non-
university, and specialized hospitals among 35 member countries of the European Society 
of Cardiology, with an ECG or Holter-proven diagnosis of atrial fibrillation during the 
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qualifying admission or in the preceding year.17 Paper-based medical records and/or data 
from medical information systems were used to populate the database. We included in the 
present analysis only the EHS patients with nonvalvular atrial fibrillation (i.e. defined by 
the absence of a mitral valve stenosis or valvular surgery) and with data available for the 
calculation of the risk scores. 
 
Risk scores.  
The CHADS2, CHA2DS2-VASc and HAS-BLED scores were retrospectively calculated 
for each patient using the data on collected at discharge from the hospital or at the end of 
the index outpatient visit. A reduced version of the HAS-BLED score was used because 
of the unavailability of data for liver dysfunction and labile INR.  
 
Statistical analysis.  
Both the CHADS2/HAS-BLED and CHA2DS2-VASc/HAS-BLED combinations of 
scores were considered. The co-classification of the study population according to each 
of those combinations was described, using either the raw scores or the score-based risk 
categories as defined in the literature2,18 (for CHADS2 and  CHA2DS2-VASc: low risk = 
score 0; intermediate risk = score 1; high risk = score ≥ 2; for HAS-BLED: low risk = 
score 0; intermediate risk = score 1-2; high risk = score ≥ 3). Cross tabulation and box-
plots were used to represent the co-distribution.  
 
A Spearman rank correlation coefficient was calculated to express the extent of 
association/dependence between the patient cardio-embolic and bleeding risk score. We 
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then used two measures of concordance/exchangeability between the two risk 
categorizations (high, intermediate and low): a) the percentage agreement, i.e. percentage 
of patients classified into the same cardio-embolic and bleeding risk category; b) a 
weighted percentage agreement, taking into account also the “partial concordance”, 
assigning a weight of 2 for perfect agreement, 1 for a 1-category disagreement, 0 for 2-
category disagreement. Symmetry and marginal homogeneity (Stuart-Maxwell) tests 
were also performed to test, in case of discordance, if there was a statistically significant 
tendency for the cardio-embolic risk category to be higher than the bleeding risk 
category, or viceversa. 
 
Secondary analyses 
a) Score co-distribution by antithrombotic therapy. We described the score co-
distribution also in subgroups of EHS patients defined according to the antithrombotic 
therapy they were prescribed at the time of the discharge from the hospital or at the end 
of the index outpatient visit, qualitatively comparing the degree of correlation in each 
group. The following subgroups of patients were defined: patients not receiving any 
antithrombotic treatment, patients receiving an antiplatelet agent and patients receiving a 
vitamin K antagonist (VKA - including patients receiving both a VKA and an antiplatelet 
agent). Patients receiving heparins were excluded from the current analyses. Our 
hypothesis for this secondary analysis was that the distribution of each risk score would 
be different in each by-treatment defined group (according to the Kruskal-Wallis rank-
test), but that the level of within patients correlations between the two types of score 
would be similar in each treatment group as in the whole population.  
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b) Score co-distribution and outcome. We explored if there was any association between 
the score co-distribution and outcome. We did that investigating if, for each cardio-
embolic risk category, there was a trend in the occurrence of adverse events according to 
the bleeding risk category, and vice-versa. Also, we investigated if, regardless of the level 
of risk, the concordance/discordance between cardio-embolic and bleeding risk categories 
was associated with a different outcome (considering stroke, bleeding or any); logistic 
regression analysis was used for this purpose. All analyses were stratified by or adjusted 
for antithrombotic treatment. Definitions used for the outcomes in the EHS on atrial 
fibrillation are provided elsewhere.2     
 
Results 
Of the 5,272 patients with atrial fibrillation in the EHS of atrial fibrillation who were 
discharged alive,17 3920 patients without mitral valve stenosis or valvular surgery and 
available data to calculate the risk scores, were included in this analysis. Table 1 shows 
relevant characteristics of the study population.  
 
Table 2 and figure 1 (panel A) describe the co-distribution of CHADS2 and HAS-
BLED; table 4 and figure 1 (panel C) describe the co-distribution of CHA2DS2-VASc 
and HAS-BLED. The Spearman correlation coefficient was 0.416 (p<0.001) between 
CHADS2 and HAS-BLED, and 0.512 (p<0.001) between CHA2DS2-VASc and HAS-
BLED. 
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Those co-distributions translated into the joint score-based risk categorizations shown in 
table 3, table 5 and in figure 1 (panel B and D). The most prevalent risk group was the 
one at high cardio-embolic risk and intermediate bleeding risk (37.5% if CHADS2, 60.8% 
if CHA2DS2-VASc was used), with 89% (CHADS2/HAS-BLED) and 97% (CHA2DS2-
VASc/HAS-BLED) of patients classified into a bleeding risk category equal or lower 
than their cardio-embolic risk category (p<0.001 for symmetry and marginal 
homogeneity tests). Using the CHADS2 and HAS-BLED, 39.6% of patients were 
classified into the same cardio-embolic and bleeding risk category, while 21.7% was the 
agreement between CHA2DS2-VASc and HAS-BLED (16.3% were classified into the 
same cardio-embolic and bleeding risk category by both the CHADS2/HAS-BLED and 
the CHA2DS2-VASc/HAS-BLED combination). Considering also the partial agreement, 
the weighted percentage agreement was 67.7% and 57.0%, respectively.  
 
Score co-distribution and antithrombotic therapy 
Table 1 describes frequencies and modalities of antithrombotic therapy prescribed at 
discharge. As expected, the distribution of each individual risk score significantly 
differed among the three by-treatment groups (p<0.001). When looking at the score co-
distribution, positive Spearman correlation coefficients were obtained in each group 
similar to those found in the whole population (supplementary table 1). The score co-
distribution across by-treatment groups is described in the supplementary figure 1. 
 
Score co-distribution and outcome 
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Data on 1-year outcome were available for 2,934 out of 3,920 patients (74.8%). The score 
co-distribution and correlation in these patients resembled those of the initial population. 
Table 6 shows, among patients on warfarin, the tendency for an increasing frequency of 
events (either stroke or bleedings, or both) as function of an increasing bleeding risk 
score, mainly evident within the high cardio-embolic risk category. Similarly, a tendency 
for an increasing frequency of events in accordance with an increasing cardio-embolic 
risk score was found within the intermediate and high bleeding risk categories. The same 
results for the entire population are provided in the supplementary table 2. Finally, a 
trend of an increasing frequency of stroke for a stronger concordance between cardio-
embolic and bleeding risk category was observed (table 7), before and after accounting 
for the antithrombotic therapy, even if without reaching a statistical significance. The 
trend was not confirmed for the occurrence of major bleedings.   
 
Discussion 
We described the joint distribution of scores for the cardio-embolic risk (CHADS2 
or CHA2DS2-VASc) and scores for the bleeding risk (HAS-BLED) in patients with atrial 
fibrillation. We found a positive within patient correlation of moderate strength between 
the two types of scores (about 0.5), in the whole population and in subgroups defined by 
the prescribed antithrombotic therapy. A perfect concordance between cardio-embolic 
and bleeding risk category was found in largely less than 50% of patients, but only from 
4.4% (CHADS2/HAS-BLED) to 7.7% (CHA2DS2-VASc/HAS-BLED) of patients fell 
into the cells corresponding to a full discordance between the cardio-embolic and 
bleeding risk category (i.e. high cardio-embolic risk/low bleeding risk, or vice-versa). An 
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increasing bleeding risk score was associated with an increasing frequency of stroke 
events within the intermediate and high cardio-embolic risk score categories; the trend 
was less evident for bleeding events. A higher degree of within patient concordance 
between cardio-embolic and bleeding risk category appeared to be associated with a 
higher frequency of stroke.   
The current literature has been focusing on verifying the predictive ability of 
proposed cardio-embolic and bleeding risk scores in real-word atrial fibrillation cohorts, 
but scarce attention has been paid to addressing the questions how those scores co-
distribute and correlate, and so how the assumption of their independence is justifiable 
and their separate use necessary. For example, Friberg et al.14 recently used the score-
based co-stratification to assess the net benefit with warfarin associated to different 
CHADS2 (or CHA2DS2-VASc) and HAS-BLED scores, in a large Swedish atrial 
fibrillation population; their cross-tabulations resemble ours (table 2 and 4), with empty 
cells at the top right and bottom left corners, and the highest concentration in the cells 
along the diagonal. Yet, they did not focus on how those strata were differently 
populated.  Lopes et al.19 reported the cardio-embolic and bleeding score-based 
categories co-distribution among the participants of the ARISTOTLE (Apixaban for 
Reduction in Stroke and Other Thromboembolism Events in Atrial Fibrillation) study. 
They calculated a weighted kappa (i.e. a measure of agreement adjusted for chance, 
which is usually used for evaluating the agreement between observers), but they did not 
report any measure of correlation between scores.  
  In fact, the relationship between cardio-embolic and bleeding risk scores has two 
important implications. First, if the two scores are used together (either in clinical 
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practice or in a risk-benefit analysis) their non-independence has to be accounted for.20 
Second, one type of score may be predicted from the other using appropriate statistics. 
Moreover, if there is not only an association but also a large degree of concordance, one 
score may be used as the surrogate for the other. In fact, according to our findings a 
patient at low, intermediate or high cardio-embolic risk would have about 30% chance of 
being either at low, intermediate or high bleeding risk. On the other hand, a generic 
patient would have a very low chance (less than 11% if CHADS2 is used, or less than 2% 
if CHA2DS2-VASc is used) to have a predicted bleeding risk higher than the predicted 
cardio-embolic risk.  
Therefore, what is the added value in clinical practice of using both scores instead 
of relying on their correlation or concordance? The added value lies in 1) improving the 
classification of those 70% of patients with incomplete concordance, also identifying 
those 2-10% patients with a bleeding risk higher that a cardio-embolic risk, and 2) 
facilitating the introduction, in an individualized decision making process, of different 
weights reflecting different patient’s values, for a cardio-embolic and a bleeding event. 
Indeed, if the patient judges a major bleeding substantially more undesirable than a 
stroke, predicting accurately the patient’s baseline risks of both events will be required to 
accommodate her values. 
Limitations 
To what extent our results are generalizable has to be established. Indeed though 
being a real-world population, the EHS cohort was a selected cohort (patients referred to 
the hospital) and mostly constituted by outpatients. This might have affected the 
distribution of each kind of score and, consequently, the type of relationship between 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 13
scores. In addition, it was an observational cohort; showing a significantly different 
distribution of risk scores across treatment groups we confirmed that treatment was not 
assigned randomly. However when the potential confounding by indication could play a 
role, we adjusted or stratified the analyses. Then, the small size of some subgroups 
limited the reliability of the estimates of the correlation coefficients. Likewise, the overall 
low number of events reduced the power of the analyses on the association between risk 
co-distribution and outcomes, and the high representation of intermediate-high risk 
categories limited their interpretation.  Another limitation that deserves attention is the 
fact that we had to resort to a reduced version of the HAS-BLED score, possibly leading 
to an underestimation of the actual scores. Finally, we used the score-based risk 
categorizations described in the literature, which is something arbitrary and proposed for 
each type of score separately; thus, the definition of low/intermediate/high risk does not 
correspond exactly to the same annualized risk for every score. 
 
Conclusions 
The low concordance between the cardio-embolic and bleeding risk stratifications we 
found leaves room to the hypothesis that their separate assessment might be important. 
The impact on patient relevant outcomes of their combined assessment needs to be 
evaluated in a large implementation study of a decision model also accounting for the 
relative importance assigned to bleedings versus strokes.  
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Figure legend 
 
Figure 1. Cardio-embolic and bleeding risk scores co-distribution. A) CHADS2 and 
HAS-BLED scores. B) CHADS2 and HAS-BLED risk categories. C) CHA2DS2-VASc 
and HAS-BLED scores. D) CHA2DS2-VASc and HAS-BLED risk categories. Red line: 
median of HAS-BLED scores. 
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Tables 
 
Table 1. Characteristics of the 3920* patients with atrial fibrillation from the Euro 
Heart Survey included in the current analyses 
 
Characteristic Description 
Age, median (Q1, Q3) 68 (59, 75) 
Women, n (%) 1,587 (40.5) 
CHADS2, median (Q1, Q3) 1 (1, 2) 
CHA2DS2-VASc, median (Q1, Q3) 3 (2, 4) 
HAS-BLED, median (Q1, Q3) 1 (1, 2) 
Drugs prescribed at discharge, n (%) 
Warfarin 
 
2,476 (63.2) 
Aspirin 1,079 (27.5) 
No antithrombotic therapy  365 (9.3) 
Stroke at 1 year of follow up, n (%) 
Any patient 
 
47 (1.6) 
In patients on warfarin 27 (1.4) 
In patients on aspirin 19 (2.5) 
In patients off antithrombotic therapy 1 (0.4) 
Major bleeding at 1 year of follow up, n (%) 
 
44 (1.5) 
35 (1.8) 
8 (1.0) 
1 (0.4) 
Any patient 
In patients on warfarin 
In patients on aspirin 
In patients off antithrombotic therapy 
Stroke and major bleeding at 1 year of follow up, n (%) 
 
4 (0.1) 
4 (0.2) 
0 (0) 
0 (0) 
Any patient 
In patients on warfarin 
In patients on aspirin 
In patients off antithrombotic therapy 
Legend: n, number. Q1, first quartile. Q3, third quartile. *Data on outcome at 1 year of follow up available 
for 2,934 out of 3,920 patients. 
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Table 2. CHADS2 and HAS-BLED scores co-distribution 
 
n (% of 
total) HAS-BLED 
CHADS2 0 1 2 3 4 5 
Any HAS-
BLED 
0 331 (8.44) 
264 
(6.73) 
83 
(2.12) 
6 
(0.15) 
0 
(0.00) 
0 
(0.00) 
684 
(17.45) 
1 314 (8.01) 
641 
(16.35) 
318 
(8.11) 
64 
(1.63) 
5 
(0.13) 
0 
(0.00) 
1,342 
(34.23) 
2 129 (3.29) 
472 
(12.04) 
369 
(9.41) 
83 
(2.12) 
7 
(0.18) 
0 
(0.00) 
1,060 
(27.04) 
3 28 (0.71) 
213 
(5.43) 
196 
(5.00) 
60 
(1.53) 
5 
(0.13) 
0 
(0.00) 
502 
(12.81) 
4 4 (0.10) 
71 
(1.81) 
77 
(1.96) 
52 
(1.33) 
10 
(0.26) 
1 
(0.03) 
215 
(5.48) 
5 0 (0.00) 
17 
(0.43) 
42 
(1.07) 
25 
(0.64) 
9 
(0.23) 
2 
(0.05) 
95 
(2.42) 
6 0 (0.00) 
5 
(0.13) 
8 
(0.20) 
6 
(0.15) 
3 
(0.08) 
0 
(0.00) 
22 
0.56 
Any 
CHADS2 
806 
(20.56) 
1,683 
(42.93) 
1,093 
(27.88) 
296 
(7.55) 
39 
(0.99) 
3 
(0.08) 3,920 
Legend: n, number. Grey cell = most prevalent cell. 
 
Table 3. CHADS2 and HAS-BLED co-distribution according to the score-based risk 
categories  
 
 
HAS-BLED risk category 
n (% of the total in each CHADS2 risk category) n (% of the total) 
CHADS2 risk 
category Low risk 
Intermediate 
risk High risk  
Low risk 331 (48.4) 347 (50.7) 6 (0.9) 684 (17.5) 
Intermediate risk 314 (23.4) 959 (71.5) 69 (5.1) 1,342 (34.2) 
High risk 161 (8.5) 1,470 (77.6) 263 (13.9) 1,894 (48.3) 
n (% of the total) 806 (20.6) 2,776 (70.8) 338 (8.6) 3,920 
Legend: n, number. Grey cell = most prevalent cell   
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Table 4. CHA2DS2-VASc and HAS-BLED scores co-distribution 
 
n (% of 
total) HAS-BLED 
CHA2DS2-
VASc 0 1 2 3 4 5 
Any HAS-
BLED 
0 218 (5.56) 
83 
(2.12) 
8 
(0.20) 
0 
(0.00) 
0 
(0.00) 
0 
(0.00) 
309 
(7.88) 
1 284 (7.24) 
239 
(6.10) 
64 
(1.63) 
7 
(0.18) 
0 
(0.00) 
0 
(0.00) 
594 
(15.15) 
2 168 (4.29) 
356 
(9.08) 
139 
(3.55) 
25 
(0.64) 
2 
(0.05) 
0 
(0.00) 
690 
(17.60) 
3 104 (2.65) 
390 
(9.95) 
269 
(6.86) 
43 
(1.10) 
3 
(0.08) 
0 
(0.00) 809 (20.64) 
4 26 (0.66) 
318 
(8.11) 
273 
(6.96) 
73 
(1.86) 
8 
(0.20) 
0 
(0.00) 
698 
(17.81) 
5 5 (0.13) 
187 
(4.77) 
170 
(4.34) 
61 
(1.56) 
3 
(0.08) 
0 
(0.00) 
426 
(10.87) 
6 1 (0.03) 
78 
(1.99) 
101 
(2.58) 
40 
(1.02) 
8 
(0.20) 
1 
(0.03) 
229 
(5.84) 
7 0 (0.00) 
20 
(0.51) 
49 
(1.25) 
33 
(0.84) 
10 
(0.26) 
0 
(0.00) 
112 
(2.86) 
8 0 (0.00) 
9 
(0.23) 
18 
(0.46) 
12 
(0.31) 
4 
(0.10) 
2 
(0.05) 
45 
(1.15) 
9 0 (0.00) 
3 
(0.08) 
2 
(0.05) 
2 
(0.05) 
1 
(0.03) 
0 
(0.00) 
8 
(0.20) 
Any 
CHA2DS2-
VASc 
806 
(20.56) 
1,683 
(42.93) 
1,093 
(27.88) 
296 
(7.55) 
39 
(0.99) 
3 
(0.08) 3,920 
Legend: n, number. Grey cell = most prevalent cell. 
 
Table 5. CHA2DS2-VASc and HAS-BLED co-distribution according to the score-
based risk categories 
 
HAS-BLED risk category 
n (% of the total in each CHA2DS2-VASc risk category) n (% of total) 
CHA2DS2-VASc risk 
category Low risk 
Intermediate 
risk High risk  
Low risk 218 (70.5) 91 (29.5) 0 (0.0) 309 (7.9) 
Intermediate risk 284 (47.8) 303 (51.0) 7 (1.2) 594 (15.1) 
High risk 304 (10.1) 2,382 (78.9) 331 (11.0) 3,017 (77.0) 
n (% of total) 806 (20.6) 2,776 (70.8) 338 (8.6) 3,920 
Legend: n, number. Grey cell = most prevalent cell 
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Table 6. Cardio-embolic and bleeding risk categories co-distribution and outcomes: 
patients prescribed with warfarin  
 
Cardio-embolic 
risk category HAS-BLED risk category 
% of patients 
experiencing a stroke 
% of patients 
experiencing a major 
bleeding 
% of patients 
experiencing a stroke 
or a major bleeding 
CHADS2 
Low risk 
Low  1.0 0.5 1.0 
Intermediate  0.0 0.8 0.8 
High  0.0 0.0 0.0 
CHADS2 
Intermediate 
risk 
Low  1.5 1.0 2.0 
Intermediate  1.1 1.8 2.7 
High  0.0 9.1 9.1 
CHADS2 
High risk 
Low 0.9 1.8 2.6 
Intermediate  1.4 1.9 3.3 
High 6.5 6.5 12.0 
 
    
CHA2DS2VASc 
Low risk 
Low  0.7 0.0 0.7 
Intermediate  0.0 0.0 0.0 
High  - - - 
CHA2DS2VASc 
Intermediate 
risk 
Low  1.6 0.5 1.6 
Intermediate  0.9 0.9 1.8 
High  0.0 0.0 0.0 
CHA2DS2VASc 
High risk 
Low  1.0 2.0 2.5 
Intermediate  1.2 1.9 3.0 
High  5.8 6.7 11.5 
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Table 7. Within patient concordance between cardio-embolic and bleeding risk 
categories and outcomes  
Cardio-embolic 
and bleeding 
risk scores 
Concordance between 
cardio-embolic and 
bleeding risk category 
% of patients 
experiencing a stroke 
[OR (95% CI)]* 
% of patients 
experiencing a major 
bleeding 
[OR (95% CI)]* 
% of patients 
experiencing a stroke 
or a major bleeding 
[OR (95% CI)]* 
CHADS2 
/HAS-BLED 
Discordance  0.8 [1.0] 
1.7 
[1.0] 
2.5 
[1.0] 
Partial Concordance† 1.5 [1.6 (0.2-11.9)] 
1.4 
[1.0 (0.2-4.2)] 
2.8 
[1.1 (0.3-3.7)] 
Concordance 1.8 [2.0 (0.3-14.9)] 
1.7 
[1.2 (0.3-5.3)] 
3.2 
[1.3 (0.4-4.3)] 
CHA2DS2VASc/
HAS-BLED 
Discordance  0.9 [1.0] 
1.8 
[1.0] 
2.3 
[1.0] 
Partial Concordance† 1.4 [1.3 (0.3-5.8)] 
1.3 
[0.8 (0.3-2.4)] 
2.7 
[1.1 (0.4-2.9)] 
Concordance 2.3 [2.1 (0.4-9.4)] 
1.8 
[1.2 (0.4-4.0)] 
4.0 
[1.7 (0.6-4.7)] 
Legend: OR, odds ratio. CI, confidence interval. 
*from logistic regressions adjusted for antithrombotic therapy 
†1-category disagreement 
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Clinical Significance 
 
• When deciding on antithrombotic therapy in patients with atrial fibrillation, the 
usefulness of a joint assessment of patient cardio-embolic and bleeding risks 
might be limited by the interdependence between the two risks 
• The degree of correlation and concordance between validated cardio-embolic and 
bleeding risk schemes has never been explicitly described  
• In a real-world population we confirmed that the available cardio-embolic and 
bleeding risk classifications are significantly correlated, but not exchangeable. 
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Supplementary Tables  
 
 
Table 1. Correlation between cardio-embolic and bleeding scores in the whole 
population and in by-treatment defined groups 
 
Cardio-embolic and bleeding 
risk scores Treatment group 
Trend for raw scores 
Spearman correlation 
coefficient (p value)* 
CHADS2/HAS-BLED 
Any (whole population) 0.416 (<0.001) 
No antithrombotic therapy 0.603 (<0.001) 
On antiplatelet agent 0.420 (<0.001) 
On VKA 0.438 (<0.001) 
CHA2DS2VASc/HAS-BLED 
Any (whole population) 0.512 (<0.001) 
No antithrombotic therapy 0.673 (<0.001) 
On antiplatelet agent 0.563 (<0.001) 
On VKA 0.582 (<0.001) 
Legend: VKA, vitamin K antagonists. 
*P value for testing if Spearman correlation coefficient is statistically significantly different from 0 
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Table 2. Cardio-embolic and bleeding risk categories co-distribution and outcomes: 
all patients  
Cardio-embolic 
risk category HAS-BLED risk category 
% of patients 
experiencing a stroke 
% of patients 
experiencing a major 
bleeding 
% of patients 
experiencing a stroke 
or a major bleeding 
CHADS2 
Low risk 
Low risk 0.7 0.4 0.7 
Intermediate risk 0.4 0.4 0.8 
High risk 0.0 0.0 0.0 
CHADS2 
Intermediate 
risk 
Low risk 1.3 0.8 1.7 
Intermediate risk 1.2 1.2 2.3 
High risk 4.3 2.1 6.4 
CHADS2 
High risk 
Low risk 0.9 1.7 2.6 
Intermediate risk 1.7 1.7 3.4 
High risk 5.6 5.1 10.2 
 
    
CHA2DS2VASc 
Low risk 
Low risk 0.6 0.0 0.6 
Intermediate risk 0.0 0.0 0.0 
High risk - - - 
CHA2DS2VASc 
Intermediate 
risk 
Low risk 1.3 0.4 1.3 
Intermediate risk 0.4 0.4 0.9 
High risk 0.0 0.0 0.0 
CHA2DS2VASc 
High risk 
Low risk 0.9 1.8 2.3 
Intermediate risk 1.5 1.5 3.0 
High risk 5.3 4.5 9.4 
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Supplementary figure 
 
Cardio-embolic and bleeding risk scores co-distribution according to antithrombotic 
therapy prescribed at discharge 
Panel A. CHADS2 and HAS-BLED 
 
Panel B. CHA2DS2-VASc and HAS-BLED 
 
Legend: red line = median of HAS-BLED scores. VKA, vitamin K antagonists. AP, antiplatelet agents. No, 
no therapy 
